A Phase III, Randomized, Double-blind, Placebo-controlled, Efficacy, and Safety Study of Balovaptan in Adults with Autism Spectrum Disorder with a 2-year Open-Label Extension

Alert

Holland Bloorview email is down due to a global Microsoft outage. All scheduled client programs and services are running as usual at this time. For more information click here.

#cc0033

A Phase III, Randomized, Double-blind, Placebo-controlled, Efficacy, and Safety Study of Balovaptan in Adults with Autism Spectrum Disorder with a 2-year Open-Label Extension

Medication Clinical Trials

Summary

Please see attached flyer for further details about this study.

Researcher(s)

Evdokia Anagnostou, MD, Melanie Penner MD FRCP(C)

Interested in participating

Please note that recruitment is closed at this time. To learn more about this study, you can also contact our study coordinator, Rianne Hastie Adams at email: rhastieadams@hollandbloorview.ca or telephone: 416-425-6220, x6515.